| Document Date: 2014-11-03 11:26:24
Open Document File Size: 94,97 KBShare Result on Facebook
City Osaka / London / / Company Shionogi & Co. Ltd. / ViiV UK / Shionogi-ViiV Healthcare LLC / ViiV Healthcare Ltd / Financial review / Pfizer / GlaxoSmithKline / HIV/AIDS / Japan Shionogi & Co. / Shionogi Inc. / Glaxosmithkline plc / / Country Japan / United States / United Kingdom / / Event Company Expansion / M&A / Business Partnership / FDA Phase / / IndustryTerm pipeline products / pharmaceutical / in-line products / pharmaceuticals / foreign healthcare reforms / with respect to product / / MedicalCondition HIV / cancer / allergy / Metabolic Syndrome / AIDS / Infectious Diseases / / Organization European Union / / Person Camilla Bull / Dominique Limet / Isao Teshirogi / David Redfern / James Dodwell / / / Position Chief Executive Officer / President and Chief Executive Officer / Analyst / Private / Chairman of the Board / / Product US / / URL www.shionogi.co.jp / www.shionogi.com / www.viivhealthcare.com / /
SocialTag |
Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav